Kenvue

Kenvue Inc.
Company type	Public
Traded as	NYSE: KVUE; S&P 500 component;
Industry	Consumer products
Predecessor	Johnson & Johnson (consumer health division); Pfizer Consumer Health (first incarnation); Pharmacia & Upjohn (consumer health division); Warner–Lambert (consumer health division);
Founded	February 23, 2022
Headquarters	Summit, New Jersey, U.S.
Area served	Worldwide
Key people	Kirk Perry (CEO); Larry Merlo (chairman);
Products	Aveeno; Band-Aid; Benadryl; Combantrin; Johnson's Baby; Listerine; Lactaid; Mylanta; Neutrogena; Trosyd; Calpol; Tylenol; Visine;
Revenue	US$15.1 billion (2025)
Operating income	US$2.41 billion (2025)
Net income	US$1.47 billion (2025)
Total assets	US$27.1 billion (2025)
Total equity	US$10.8 billion (2025)
Number of employees	c. 22,000 (2025)
Subsidiaries	McNeil Consumer Healthcare
Website	kenvue.com
	Footnotes / references;

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.

Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.

CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Perry was appointed the company's permanent CEO in November 2025.

The company has also faced controversy, including a securities class action filed in 2023 alleging misleading disclosures regarding risks related to phenylephrine, which led to its stock trading below IPO levels.

On November 3, 2025, Kimberly-Clark announced that it was acquiring Kenvue for a total enterprise value of US$48.7 billion. The acquisition is expected to close around the second half of 2026.